BoxA from HMGB1, human & mouse, LPS-free - 25 µg

BoxA: A Highly Conserved HMGB1 DNA Binding Domain and Its Therapeutic Potential

Overview: BoxA is a highly conserved DNA-binding domain of the HMGB1 protein, a member of the High Mobility Group Box (HMG Box) family. It functions as an antagonist by preventing HMGB1 from binding to its receptor, RAGE, thereby inhibiting the downstream cytokine effects of HMGB1. The BoxA used in this context is derived from human and mouse HMGB1 sequences, ensuring its exact match and minimal immunological response due to its self-antigen nature.

Therapeutic Potential:

1. Sepsis Protection:
• Study Reference: Yang et al., 2004, Proc Natl Acad Sci USA, 101:296-301
• Findings: BoxA has demonstrated protective effects against sepsis in a mouse peritonitis model. It mitigates the systemic inflammation and severe outcomes associated with sepsis, highlighting its potential as a therapeutic agent in sepsis management.
2. Hepatitis Mitigation:
• Study Reference: Sitia et al., 2007, J Leukoc Biol, 81:100-7
• Findings: BoxA reduces hepatitis symptoms in a mouse model of Hepatitis B Virus (HBV) infection. Its ability to modulate liver inflammation and damage points to its utility in treating viral hepatitis and potentially other liver conditions.
3. Dendritic Cell Modulation:
• Study Reference: Dumitriu et al., 2005, J Immunol, 174:7506-15
• Findings: BoxA inhibits the maturation and activation of dendritic cells. It also affects subsequent T cell responses, including proliferation, survival, and Th1 differentiation, all induced by HMGB1. This modulation of dendritic cell function suggests its potential for regulating immune responses and autoimmune diseases.
4. Inhibition of HMGB1 Activity:
• Findings: BoxA blocks the chemotactic activity of HMGB1 on endothelial cells and fibroblasts and inhibits its mitogenic activity on stem cells. By interfering with these HMGB1-mediated processes, BoxA holds promise as a therapeutic agent in conditions characterized by excessive HMGB1 activity, such as chronic inflammation and cancer.

Significance: BoxA’s ability to inhibit various HMGB1-mediated activities underscores its potential as a therapeutic agent. Its applications could extend to managing conditions such as sepsis, hepatitis, autoimmune diseases, and cancer, where HMGB1 plays a critical role. The conserved nature of BoxA ensures broad applicability and minimal risk of immunogenicity, making it a promising candidate for further therapeutic development.

This Immunoassay from Tecan IBL International is for research use only.

Tecan IBL International offers a comprehensive range of ELISAs, immunoassays, antibodies and recombinant proteins.
Explore the full range >